Mostrando 10 resultados de: 18
Filtros aplicados
Publisher
Drug Metabolism and Drug Interactions(2)
Pharmacogenomics Journal(2)
Clinical Chemistry and Laboratory Medicine(1)
Clinical Pharmacology & Therapeutics(1)
Clinical Pharmacology and Therapeutics(1)
Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: Application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship
ArticleAbstract: The drug-metabolizing cytochrome P450 (CYP) enzyme CYP2D6 is involved in the metabolism of several cPalabras claves:CYP2D6, debrisoquine, HPLC, Metabolic ratioAutores:Adrián LLerena, Berecz R., Cáceres M.C., Cobaleda J., Dorado P., González I.Fuentes:scopusDEBRISOQUINE HYDROXYLATION PHENOTYPES IN HEALTHY VOLUNTEERS
OtherAbstract:Palabras claves:Autores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J.Fuentes:scopusDebrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents
ArticleAbstract: Debrisoquin and S‐mephenytoin hydroxylation phenotypes were determined in 72 Spanish psychiatric patPalabras claves:Autores:Adrián LLerena, Cobaleda J., Dahl M.L., Herraiz A., Johansson I.Fuentes:scopusDebrisoquin oxidation polymorphism in a Spanish population
ArticleAbstract: The capacity for debrisoquin metabolism was determined in 377 healthy Spanish volunteers by measurinPalabras claves:Autores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J.Fuentes:scopusDebrisoquine oxidation in schizophrenic patients treated with neuroleptics
ArticleAbstract:Palabras claves:debrisoquine, Neuroleptics, OXIDATION, SchizophreniaAutores:Adrián LLerena, Benitez Rodriguez J., Buemi A.L., Caputi A.P., Cobaleda J., García M.A., Piña B., Spina E.Fuentes:scopusDebrisoquine oxidation phenotype in psychiatric patients.
ArticleAbstract:Palabras claves:Autores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J., García M.A., Martínez C., Piñas B.Fuentes:scopusAcetylator polymorphism in Parkinson's disease
ArticleAbstract: Acetylator phenotype has been determined using sulphamethazine in 100 patients with Parkinson's disePalabras claves:acetylator phenotype, debrisoquine oxidation, drug polymorphism, Parkinsonism, sulphamethazineAutores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J., Fernandez-Gundin M.J., Jimenez F.J., Ladero J.M., Martinez C., Muñoz J.J.Fuentes:scopusHigh frequency of CYP2D6 ultrarapid metabolizers in Spain: Controversy about their misclassification in worldwide population studies
ArticleAbstract: A high frequency (7-10%) of CYP2D6 ultrarapid metabolizers estimated from the genotype (gUMs) has bePalabras claves:Autores:Adrián LLerena, Cobaleda J., de Andrés F., Delgado A., Naranjo M.E.G., Penãs-Lledó E.M.Fuentes:scopusOxidative polymorphism of debrisoquine in Parkinson's disease
ArticleAbstract: Oxidative phenotype and metabolic ratio (MR) of debrisoquine (DBQ) have been determined in 87 patienPalabras claves:Autores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J., Jimenez-Jimenez F.J., Ladero J.M., Martínez C., Muñoz J.J., Puerto A.M., Valdivielso M.J.Fuentes:scopusInterethnic differences in UGT1A4 genetic polymorphisms between Mexican Mestizo and Spanish populations
ArticleAbstract: UDP-glucuronosyltransferase 1A4 (UGT1A4) is a phase II drug-metabolizing enzyme that catalyzes the gPalabras claves:Glucuronidation, Interethnic differences, Mexican-Mestizo, Spaniards, UGT1A4Autores:Adrián LLerena, Alonso M.E., Cobaleda J., Dorado P., Gallego-Aguilera A., López M.L., MELANIE BRIGETTE ARROYO LOPEZ, Monroy-Jaramillo N., Ortega A., Penãs-Lledó E.M., Silva-Zolezzi I.Fuentes:googlescopus